Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real-World Clinical Practice.

ABSTRACT:

Background

Echinocandins are the first-line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once-weekly intravenous administration, offering potential advantages in complex clinical settings.

Objectives

We aimed to describe our real-world experience with rezafungin for the treatment of invasive fungal disease (IFD).

Patients

A retrospective analysis of consecutive patients treated with rezafungin for proven IFD at our center between September 2022 and December 2025 was conducted.

Results

We included 13 patients (mean age: 59.4 ± 17.8 years). Main predisposing conditions included immunosuppression (53.8% [solid organ transplantation in 30.8%]), solid cancer (30.8%) and recent surgical

SUBMITTER: Boan J 

PROVIDER: S-EPMC12922572 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature